Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

Inclusion Criteria: * Adults, age 18 and over * Previous diagnosis of biopsy-proven NLD * Active NLD lesions, defined as * clinical signs of inflammation, for example erythematous margins, sensations of itch, pain, dysaesthesia * lesions increasing in size or appearance of new lesions within the last 3 months * ulcerations * Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed. Exclusion Criteria: * History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold test at screening. * Are currently pregnant, breastfeeding, or planning to get pregnant during the study. * Previous hypersensitivity reaction to secukinumab or to any of the components. * History of Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) * Allergy to Latex * Currently on any other immunosuppressant systemic medication or within 28 days of baseline visit * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 16 weeks after stopping treatment. * Subjects with a serum creatinine level exceeding 176.8 μmol/L (2.0 mg/dL) * Screening total WBC count \<2,500/μL, or platelets \<100,000/μL or neutrophils \<1,500/μL or hemoglobin \<8.5 g/dL * Known infection with HIV, hepatitis B or hepatitis C at screening or randomization. Patients who are Hepatitis B Core antibody and/or Hep B Surface Antigen positive will be excluded from this study. Patients who are Hepatitis C ab positive will also be excluded from this study. * History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for non-melanoma skin cancer and carcinoma in situ of the cervix) * Are participating in another study using an investigational agent or procedure during participation in this study or within 28 days prior to baseline visit. * Plans for administration of live vaccines during the study period or 6 weeks prior to randomization * Any other procedural treatment for NLD with 28 days prior to baseline visit, including phototherapy, surgical intervention, laser therapy, or cryotherapy. * Any other active skin disease or condition (e.g., bacterial, fungal or viral infection) that may interfere with assessment of NLD; * Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy